Amphastar Pharmaceuticals Q3 revenue beats estimates

Amphastar Pharmaceuticals,

06/11/2025 21:51

Overview

Amphastar Q3 revenue of $191.8 mln beats analyst expectations

Adjusted EPS for Q3 at $0.93, surpassing consensus estimates

Company received FDA approval and launched iron sucrose injection

Outlook

Company expects strategic pipeline expansion to drive long-term growth

Amphastar anticipates revenue growth from new iron sucrose injection

Company sees growth potential in novel peptides targeting oncology and ophthalmology

Result Drivers

BAQSIMI SALES - Double-digit growth in BAQSIMI sales due to increased unit volumes from expanded marketing efforts in the U.S.

IRON SUCROSE LAUNCH - Launch of iron sucrose injection contributed to revenue growth, expanding patient access to affordable therapies

LICENSING AGREEMENT - Strategic licensing agreement with Nanjing Anji Biotechnology to develop novel peptides for oncology and ophthalmology markets

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$191.84 mln
$187 mln (6 Analysts)
Q3 Adjusted EPS
Beat
$0.93
$0.85 (6 Analysts)
Q3 EPS
$0.37
Q3 Adjusted Net Income
Beat
$44.70 mln
$41.90 mln (5 Analysts)
Q3 Net Income
$17.35 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Amphastar Pharmaceuticals Inc is $35.00, about 27.7% above its November 5 closing price of $25.31

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 6 three months ago

Press Release: ID:nACSTr3wba

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)